ERBB2 and breast cancer: Recruitment is complete and results awaited for the HER2CLIMB-02 trial (NCT03975647), a phase III study that will evaluate efficacy and safety of tucatinib or placebo plus T-DM1 in patients with unresectable locally advanced or metastatic HER2-positive BC previously treated with taxane and trastuzumab in any setting.